Company profile: Point Biopharma
1.1 - Company Overview
Company description
- Provider of radioligand therapies for cancer, with a globally focused platform for the clinical development and commercialization of radioligands. Combines a portfolio of radiopharmaceutical assets with a seasoned management team and expertise in radioisotopes.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Point Biopharma
Adaptimmune
HQ: United Kingdom
Website
- Description: Provider of T-cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases, including afami-cel, a single-dose T-cell therapy targeting cancer, and lete-cel, a single-dose T-cell therapy in development for treating solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adaptimmune company profile →
Kronos Bio
HQ: United States
Website
- Description: Provider of oncology therapies that modulate historically undruggable cancer targets. Pipeline includes KB-0742, a CDK9 inhibitor in phase 1/2 for MYC-dependent tumors, and KB-9558 targeting the p300 KAT domain for multiple myeloma. Offers a Small Molecule Microarray screening platform for transcription factor binding assays and a discovery collaboration with Genentech.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kronos Bio company profile →
Adaptive Biotechnologies
HQ: United States
Website
- Description: Provider of immune system-based products to diagnose and treat disease, including clonoSEQ, an FDA-cleared service for detecting and monitoring minimal residual disease in bone marrow from patients with certain blood cancers; immunoSEQ, a tool for profiling and monitoring the adaptive immune response, aiding research across multiple disease areas; and T-Detect COVID, a diagnostic using T cell markers, authorized for emergency use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adaptive Biotechnologies company profile →
ProfoundBio
HQ: United States
Website
- Description: Provider of antibody-based cancer therapeutics, including antibody-drug conjugates. Clinical-stage pipeline includes Rina-S, a folate receptor alpha-targeting ADC for ovarian and other solid tumors (Phase 2); PRO1160, a CD70-targeting ADC for solid tumors and hematological malignancies (Phase 1/2); PRO1107, a PTK7-targeted ADC with a hydrophilic MMAE-based linker-drug (Phase 1/2); and PRO1286, a bispecific EGFR/cMET ADC (trials anticipated in 2024).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProfoundBio company profile →
Rain Oncology
HQ: United States
Website
- Description: Provider of precision oncology therapies targeting oncogenic drivers, developing milademetan, an oral small molecule inhibitor of the p53-MDM2 complex for various cancers. Clinical programs include MANTRA (Phase 3 in dedifferentiated liposarcoma), MANTRA-2 (Phase 2 in TP53 wildtype/MDM2-amplified solid tumors), and MANTRA-4 (Phase 1/2 with atezolizumab in CDKN2A loss, TP53 wildtype tumors).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rain Oncology company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Point Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Point Biopharma
2.2 - Growth funds investing in similar companies to Point Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Point Biopharma
4.2 - Public trading comparable groups for Point Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →